Oh, Jee Hye
(Department of Family Medicine, The Catholic University of Korea College of Medicine)
,
Lee, Yong Joo
(Department of Family Medicine, The Catholic University of Korea College of Medicine)
,
Seo, Min Seok
(Department of Family Medicine, The Catholic University of Korea College of Medicine)
,
Yoon, Jo Hi
(Department of Family Medicine, The Catholic University of Korea College of Medicine)
,
Kim, Chul Min
(Department of Family Medicine, The Catholic University of Korea College of Medicine)
,
Kang, Chung
(Department of Family Medicine, The Catholic University of Korea College of Medicine)
목적: Palliative Performance Scale (PPS)는 진행성 암환자에서 널리 사용되는 예후도구이다. PPS 측정이 생존에 대한 예측을 의미하지만, 연속적인 PPS 측정에 대한 유용성은 추가적인 연구가 필요하다. 본 연구에서는 완화 병동에 입원한 진행성 암환자를 대상으로 PPS score의 변화와 생존간의 연관성에 대해 진행한 연구이다. 방법: 2010년 1월부터 2012년 12월까지 서울성모병원 완화의학과에 입원한 환자 606에 대한 의무기록을 통하여 입원 당일의 PPS score와 입원 3일째의 PPS score 그리고, 두 score의 차이를 측정하여 점수의 변화와 생존간의 관련성을 분석하였다. 결과: PPS score의 변화와 생존과는 통계적으로 유의한 관련이 있었다. PPS score의 변화가 30% 이하인 군과 비교하였을 때, 30% 초과된 군에서 hazard ratio가 2.66(95% CI 2.19~3.22)로 확인되었다. 입원 3일째 PPS score가 30% 이하인 경우 독립적으로 생존에 대한 예측이 가능하였으며, PPS score 30% 초과된 군과 비교했을 때 hazard ratio는 1.67 (95% CI 1.38~2.02)로 확인되었다. 입원 당시의 PPS score는 생존과 독립적인 관련성은 없었다. 결론: 후향적으로 의무기록 분석을 통해 이루어진 본 연구에서 30% 이상의 PPS score 변화는 입원중인 말기 암환자의 생존과의 관련이 확인되었다. 입원 당시의 PPS score는 생존을 예측하지 못했다. PPS score의 변화는 말기암환자에서 단일 PPS score 측정보다 더 민감한 지표일 수 있다. 차후 더 많은 환자들에서 이에 대한 다기관, 전향적 연구가 필요하다.
목적: Palliative Performance Scale (PPS)는 진행성 암환자에서 널리 사용되는 예후도구이다. PPS 측정이 생존에 대한 예측을 의미하지만, 연속적인 PPS 측정에 대한 유용성은 추가적인 연구가 필요하다. 본 연구에서는 완화 병동에 입원한 진행성 암환자를 대상으로 PPS score의 변화와 생존간의 연관성에 대해 진행한 연구이다. 방법: 2010년 1월부터 2012년 12월까지 서울성모병원 완화의학과에 입원한 환자 606에 대한 의무기록을 통하여 입원 당일의 PPS score와 입원 3일째의 PPS score 그리고, 두 score의 차이를 측정하여 점수의 변화와 생존간의 관련성을 분석하였다. 결과: PPS score의 변화와 생존과는 통계적으로 유의한 관련이 있었다. PPS score의 변화가 30% 이하인 군과 비교하였을 때, 30% 초과된 군에서 hazard ratio가 2.66(95% CI 2.19~3.22)로 확인되었다. 입원 3일째 PPS score가 30% 이하인 경우 독립적으로 생존에 대한 예측이 가능하였으며, PPS score 30% 초과된 군과 비교했을 때 hazard ratio는 1.67 (95% CI 1.38~2.02)로 확인되었다. 입원 당시의 PPS score는 생존과 독립적인 관련성은 없었다. 결론: 후향적으로 의무기록 분석을 통해 이루어진 본 연구에서 30% 이상의 PPS score 변화는 입원중인 말기 암환자의 생존과의 관련이 확인되었다. 입원 당시의 PPS score는 생존을 예측하지 못했다. PPS score의 변화는 말기암환자에서 단일 PPS score 측정보다 더 민감한 지표일 수 있다. 차후 더 많은 환자들에서 이에 대한 다기관, 전향적 연구가 필요하다.
Purpose: The Palliative Performance Scale (PPS) is a widely used prognostic tool in patients with advanced cancer. This study examines the association between changes in PPS score and survival in patients with advanced cancer. Methods: We identified a cohort of 606 inpatients who died at a Korean un...
Purpose: The Palliative Performance Scale (PPS) is a widely used prognostic tool in patients with advanced cancer. This study examines the association between changes in PPS score and survival in patients with advanced cancer. Methods: We identified a cohort of 606 inpatients who died at a Korean university hospital's hospice/palliative care center. For each patient, the PPS score was measured twice according to a standard procedure: 1) upon admission, and 2) three days after admission (D3). "Change on D3" was defined as a difference between initial PPS and PPS on D3. We used a Cox regression modeling approach to explore the association between this score change and survival. Results: The changes in scores were associated with survival. A score change of >30% yielded a hazard ratio for death of 2.66 (95% CI 2.19~3.22), compared to a score change of ${\leq}30%$. PPS of ${\leq}30$ on D3 also independently predicted survival, with a hazard ratio of 1.67 (95% CI 1.38~2.02) compared to PPS of >30. Conclusion: A change of over 30% in PPS appears to predict survival in hospitalized patients with terminal cancer, even after adjustment for confounders. Changes in PPS may be a more sensitive indicator of impending death than a single PPS measured on the day of admission in terminal cancer patients. Further prospective study is needed to examine this important finding in other populations.
Purpose: The Palliative Performance Scale (PPS) is a widely used prognostic tool in patients with advanced cancer. This study examines the association between changes in PPS score and survival in patients with advanced cancer. Methods: We identified a cohort of 606 inpatients who died at a Korean university hospital's hospice/palliative care center. For each patient, the PPS score was measured twice according to a standard procedure: 1) upon admission, and 2) three days after admission (D3). "Change on D3" was defined as a difference between initial PPS and PPS on D3. We used a Cox regression modeling approach to explore the association between this score change and survival. Results: The changes in scores were associated with survival. A score change of >30% yielded a hazard ratio for death of 2.66 (95% CI 2.19~3.22), compared to a score change of ${\leq}30%$. PPS of ${\leq}30$ on D3 also independently predicted survival, with a hazard ratio of 1.67 (95% CI 1.38~2.02) compared to PPS of >30. Conclusion: A change of over 30% in PPS appears to predict survival in hospitalized patients with terminal cancer, even after adjustment for confounders. Changes in PPS may be a more sensitive indicator of impending death than a single PPS measured on the day of admission in terminal cancer patients. Further prospective study is needed to examine this important finding in other populations.
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
문제 정의
Because this study is performed in a single tertiary hospice/palliative hospital, the result cannot be a standard to general population. And we could not gain the whole data from the all patients admitted in same time due to a nature of retrospective studies. We could not analyze other prognostic factors (38-40).
These late referral to hospice and palliative care is one of the important issues of palliative care system in Korea (18) which result in relatively short duration of palliative care services than other countries (19). Moreover, admissions at impending death status, unexpected death, and long admission waiting times are thought to be other reasons of short survival time in this study.
Because physicians usually predict patients’ survival time by the changes or declining pace of performance status, changes of PPS also contains possibility as an objective prognostic tool. The aim of this study is to evaluate the prognostic value of PPS changes and degree of PPS changes in terminal cancer inpatients.
PPS 측정이 생존에 대한 예측을 의미하지만, 연속적인 PPS 측정에 대한 유용성은 추가적인 연구가 필요하다. 본 연구에서는 완화 병동에 입원한 진행성 암환자를 대상으로 PPS score의 변화와 생존간의 연관성에 대해 진행한 연구이다.
제안 방법
In this study, age, sex, type of cancer, PPS, and survival time were collected by the review of medical record. Survival time was defined as the duration between admission and expired date.
방법: 2010년 1월부터 2012년 12월까지 서울성모병원 완화의학과에 입원한 환자 606에 대한 의무기록을 통하여 입원 당일의 PPS score와 입원 3일째의 PPS score 그리고, 두 score의 차이를 측정하여 점수의 변화와 생존간의 관련성을 분석하였다.
성능/효과
Multivariate Cox regression analyses were examined to evaluate hazard ration of PPS at D3 and PPS changes at D3. Adjusting age, sex, and type of cancer, PPS at D3 below 30% showed significant higher hazard ratio of 1.67 and 40% showed insignificant hazard ratio compared with PPS at D350%. PPS changes at D3 over 30% showed significant higher hazard ratio of 2.
66 at week 1 and with 2, respectively. Consistent with previous findings, our results revealed that PPS change even in 3 days assessment was significantly associated with survival in patients with terminal cancer.
However, pace of declining patient’s condition often provide crucial information to predict appropriate prognosis. In this study, both change of PPS at D3 below 30% and degree of PPS changes at D3 over 30% were independent predictors of survival time when we adjusted for sex, age, and cancer type. Among the significant prognostic factors, degree of changes in PPS in D3 showed strongest hazard ratio.
PPS score의 변화가 30% 이하인 군과 비교하였을 때, 30% 초과된 군에서 hazard ratio가 2.66(95% CI 2.19∼3.22)로 확인되었다.
The number of males was 292 and female was 313. The number of each PPS score at admission from 10% to 70% showed 15, 21, 71, 178, 188, 99, 34 and PPS at D3 from 0 to 70% showed 81, 27, 40, 73, 170, 125, 65, and 25 each. The most common cancer type was stomach cancer with 121 patients following 95 colorectal cancer, 88 lung cancer, 71 hepatobiliary cancer, 48 pancreas cancer, 41 ovary/cervix cancer.
결과: PPS score의 변화와 생존과는 통계적으로 유의한 관련이 있었다. PPS score의 변화가 30% 이하인 군과 비교하였을 때, 30% 초과된 군에서 hazard ratio가 2.
결론: 후향적으로 의무기록 분석을 통해 이루어진 본 연구에서 30% 이상의 PPS score 변화는 입원중인 말기암환자의 생존과의 관련이 확인되었다. 입원 당시의 PPS score는 생존을 예측하지 못했다.
입원 3일째 PPS score가 30% 이하인 경우 독립적으로 생존에 대한 예측이 가능하였으며, PPS score 30% 초과된 군과 비교했을 때 hazard ratio는 1.67 (95% CI 1.38∼2.02)로 확인되었다.
후속연구
목적: Palliative Performance Scale (PPS)는 진행성 암환자에서 널리 사용되는 예후도구이다. PPS 측정이 생존에 대한 예측을 의미하지만, 연속적인 PPS 측정에 대한 유용성은 추가적인 연구가 필요하다. 본 연구에서는 완화 병동에 입원한 진행성 암환자를 대상으로 PPS score의 변화와 생존간의 연관성에 대해 진행한 연구이다.
PPS score의 변화는 말기암환자에서 단일 PPS score 측정보다 더 민감한 지표일 수 있다. 차후 더 많은 환자들에서 이에 대한 다기관, 전향적 연구가 필요하다.
참고문헌 (40)
Allin KH, Nordestgaard BG. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci 2011;48:155-70.
Caraceni A, Nanni O, Maltoni M, Piva L, Indelli M, Arnoldi E, et al. Impact of delirium on the short term prognosis of advanced cancer patients. Italian Multicenter Study Group on Palliative Care. Cancer 2000;89:1145-9.
Kersten C, Louhimo J, Algars A, Lahdesmaki A, Cvancerova M, Stenstedt K, et al. Increased C-reactive protein implies a poorer stage-specific prognosis in colon cancer. Acta Oncol 2013; 52:1691-8.
Lee SY, Lee YJ, Yang JH, Kim CM, Choi WS. The Association between Phase Angle of Bioelectrical Impedance Analysis and Survival Time in Advanced Cancer Patients: Preliminary Study. Korean J Fam Med 2014;35:251-6.
Lee YJ, Suh SY, Choi YS, Shim JY, Seo AR, Choi SE, et al. EORTC QLQ-C15-PAL quality of life score as a prognostic indicator of survival in patients with far advanced cancer. Support Care Cancer 2014;22:1941-8.
Suh SY, Choi YS, Yeom CH, Kwak SM, Yoon HM, Kim DG, et al. Interleukin-6 but not tumour necrosis factor-alpha predicts survival in patients with advanced cancer. Supportive Care in Cancer 2013;21:3071-7.
Yoon J, Ahn SH, Lee YJ, Kim CM. Hyponatremia as an independent prognostic factor in patients with terminal cancer. Support Care Cancer 2015;23:1735-40.
Anderson F, Downing GM, Hill J, Casorso L, Lerch N. Palliative performance scale (PPS): a new tool. J Palliat Care 1996;12:5-11.
Downing M, Lau F, Lesperance M, Karlson N, Shaw J, Kuziemsky C, et al. Meta-analysis of survival prediction with Palliative Performance Scale. J Palliat Care 2007;23:245-52; discussion 252-4.
Lau F, Bell H, Dean M, Downing M, Lesperance M. Use of the Palliative Performance Scale in survival prediction for terminally ill patients in Western Newfoundland, Canada. J Palliat Care 2008;24:282-4.
Lau F, Downing M, Lesperance M, Karlson N, Kuziemsky C, Yang J. Using the Palliative Performance Scale to provide meaningful survival estimates. J Pain Symptom Manage 2009;38:134-44.
Myers J, Kim A, Flanagan J, Selby D. Palliative performance scale and survival among outpatients with advanced cancer. Support Care Cancer 2015;23:913-8.
Weng LC, Huang HL, Wilkie DJ, Hoenig NA, Suarez ML, Marschke M, et al. Predicting survival with the Palliative Performance Scale in a minority-serving hospice and palliative care program. J Pain Symptom Manage 2009;37:642-8.
Lau F, Downing GM, Lesperance M, Shaw J, Kuziemsky C. Use of Palliative Performance Scale in end-of-life prognostication. J Palliat Med 2006;9:1066-75.
Lee YJ, Yang JH, Lee JW, Yoon J, Nah JR, Choi WS, et al. Association between the duration of palliative care service and survival in terminal cancer patients. Support Care Cancer 2015;23:1057-62.
Arai Y, Okajima Y, Kotani K, Tamba K. Prognostication based on the change in the palliative prognostic index for patients with terminal cancer. J Pain Symptom Manage 2014;47:742-7.
Kao CY, Hung YS, Wang HM, Chen JS, Chin TL, Lu CY, et al. Combination of initial palliative prognostic index and score change provides a better prognostic value for terminally ill cancer patients: a six-year observational cohort study. J Pain Symptom Manage 2014;48:804-14.
Peng MT, Liu CT, Hung YS, Kao CY, Chang PH, Yeh KY, et al. Sequential Assessments of the Eastern Cooperative Oncology Group Performance Scale Enhance Prognostic Value in Patients With Terminally Ill Cancer Receiving Palliative Care. Am J Hosp Palliat Care 2016;33:471-6.
Seow H, Barbera L, Dudgeon D, Howell D, Husain A, Atzema C, et al. The association of the palliative performance scale and hazard of death in an ambulatory cancer population. J Palliat Med 2013;16:156-62.
Hilliard N, Brown S, Mitchinson S. A case report of dexmedetomidine used to treat intractable pain and delirium in a tertiary palliative care unit. Palliat Med 2015;29:278-81.
Strand JJ, Feely MA, Kramer NM, Moeschler SM, Swetz KM. Palliative Sedation and What Constitutes Active Dying: A Case of Severe Progressive Dystonia and Intractable Pain. Am J Hosp Palliat Care 2016;33:363-8.
Gioulbasanis I, Georgoulias P, Vlachostergios PJ, Baracos V, Ghosh S, Giannousi Z, et al. Mini Nutritional Assessment (MNA) and biochemical markers of cachexia in metastatic lung cancer patients: interrelations and associations with prognosis. Lung Cancer 2011;74:516-20.
Jin C, Li J, Wang Y, Chen X, Che Y, Liu X, et al. Impact of cellular immune function on prognosis of lung cancer patients after cytokine-induced killer cell therapy. Asian Pac J Cancer Prev 2014;15:6009-14.
Kimura M, Naito T, Kenmotsu H, Taira T, Wakuda K, Oyakawa T, et al. Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer. Support Care Cancer 2015;23:1699-708.
Li Y, Jin ZC, Cai Y, Ji MS, Liu J. Value of serum procalcitonin in evaluating the prognosis of sepsis in elderly patients with colorectal cancer undergoing emergency colorectal surgery. Indian J Surg 2013;75:86-93.
Wang J, Zhou W, Xu L, Yang M, Meng L, Fan W, et al. Risk factors and prognosis of lung cancer combined with pulmonary embolism. Zhongguo Fei Ai Za Zhi 2011;14:780-4.
Wu D, Tao J, Ding J, Qu P, Lu Q, Zhang W. Interleukin-11, an interleukin-6-like cytokine, is a promising predictor for bladder cancer prognosis. Mol Med Rep 2013;7:684-8.
Yoshitomi M, Yutani S, Matsueda S, Ioji T, Komatsu N, Shichijo S, et al. Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis. Exp Ther Med 2013;3:463-9.
Peng M, Liu C, Hung Y, Kao C, Chang P, Yeh K, et al. Sequential Assessments of the Eastern Cooperative Oncology Group Performance Scale Enhance Prognostic Value in Patients With Terminally Ill Cancer Receiving Palliative Care. Am J Hosp Palliat Care 2016;33:471-6.
Alsirafy SA, Sroor MY, Al-Shahri MZ. Predictive impact of electrolyte abnormalities on the admission outcome and survival of palliative care cancer referrals. J Palliat Med 2009;12:177-80.
Glare P. Clinical predictors of survival in advanced cancer. J Support Oncol 2005;3:331-9.
Vigano A, Bruera E, Jhangri GS, Newman SC, Fields AL, Suarez-Almazor ME. Clinical survival predictors in patients with advanced cancer. Arch Intern Med 2000;160:861-8.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.